Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer
Sayed Reshad Ghafouri, Suvarna Guvvala, Catherine Jones, Alexander Philipovskiy
DOI: 10.1136/jim-2021-002298 Published 15 August 2022
Sayed Reshad Ghafouri
1
Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA
Suvarna Guvvala
1
Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA
Catherine Jones
2
Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas, USA
Alexander Philipovskiy
3
Texas Tech University Health Sciences Medical Center, Lubbock, Texas, USA

Submit a Response to This Article
No eLetters have been published for this article.
Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer
Sayed Reshad Ghafouri, Suvarna Guvvala, Catherine Jones, Alexander Philipovskiy
Journal of Investigative Medicine Aug 2022, 70 (6) 1329-1341; DOI: 10.1136/jim-2021-002298

Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer
Sayed Reshad Ghafouri, Suvarna Guvvala, Catherine Jones, Alexander Philipovskiy
Journal of Investigative Medicine Aug 2022, 70 (6) 1329-1341; DOI: 10.1136/jim-2021-002298